This phase 1/2 trial assessed HER2 BATs combined with pembrolizumab in metastatic breast cancer, finding the regimen safe and well tolerated with stable disease as the best response in 17 evaluable patients.
Lawrence G. Lum, MD, DSc
Advertisement
Articles by Lawrence G. Lum, MD, DSc
In a 12-patient multiple myeloma pilot study, researchers demonstrated that anti-CD3 and anti-CD20 bispecific antibody (CD20Bi) activated both cellular and humoral anti-myeloma immunity that was detectable after patients received an autologous stem cell transplant.
Advertisement
Latest Updated Articles
- Immunotherapy Prior to Stem Cell Transplant in Multiple Myeloma
December 10th 2013
Advertisement
Advertisement
Trending on CancerNetwork
1
Where Does LAG-3/PD-1 Inhibition Fit In PD-1–Refractory Hodgkin Lymphoma?
2
Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial
3
VS-7375 Exhibits Activity in KRAS G12D–Mutated Solid Tumors
4
Offering Hope and Support Toward the Cancer Survivorship Journey
5